Sun K X, Yan C L, Li Z Y, Liu P, Zhang W, He Q
Department of Clinical Laboratory, Peking University First Hospital, Beijing 100034, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Apr 18;52(2):234-239. doi: 10.19723/j.issn.1671-167X.2020.02.007.
To explore the clinical value of serum isoform [-2] proprostate-specific antigen (p2PSA) and its derivatives %p2PSA and prostate health index (PHI) in predicting aggressive prostate cancer (PCa).
The pre-operation serum and basic clinical data of 322 patients with PCa (including 143 patients diagnosed with PCa by transrectal ultrasound-guided prostate biopsy and 179 patients undergoing radical prostatectomy) in Peking University First Hospital were collected from August 2015 to May 2018. Serum total prostate-specific antigen (tPSA), free prostate antigen (fPSA) and fPSA/tPSA (f/t) and the p2PSA level of all these patients were measured on automatic immune analyzers DxI800, and then %p2PSA and PHI were calculated. The prostate pathologic result was considered as the gold standard to evaluate the Gleason score of the patients with PCa. Receiver operator curves (ROC) were used to assess the ability of p2PSA, %p2PSA and PHI to predict aggressive PCa (pathologic Gleason score≥7) compared with those traditional markers tPSA, fPSA and f/t.
Among these patients, the p2PSA, %p2PSA and PHI median levels were significantly higher in patients with pathologic Gleason score≥7 than those with Gleason score<7 (p2PSA: 30.22 ng/L vs. 18.33 ng/L; %p2PSA: 2.50 vs. 1.27; PHI: 91.81 vs. 35.44; all P<0.01). The area under curve (AUC) of %p2PSA and PHI (0.770, 0.760) in predicting Gleason score≥7 were higher than those of the traditional indicators tPSA, fPSA and f/t (AUC were 0.648, 0.536 and 0.693, respectively). Among those patients diagnosed with PCa by transrectal ultrasound-guided prostate biopsy, the AUC of %p2PSA and PHI (AUC were 0.808 and 0.801, respectively) in predicting Gleason score≥7 were higher than those of the traditional indicators tPSA, fPSA and f/t (AUC were 0.729, 0.655 and 0.665 respectively). Among those patients undergoing radical prostatectomy, PHI and %p2PSA also had the trend of higher predictive value than those of the traditional indicators. The AUC of %p2PSA and PHI were 0.798 and 0.744, respectively while the AUC of tPSA, fPSA and f/t were 0.625, 0.507 and 0.697, respectively.
Compared with traditional markers tPSA, fPSA and f/t, %p2PSA and PHI had much higher predictive value for aggressive PCa, which may help clinicians to evaluate the therapeutic regime and make more appropriate management plan for the patients.
探讨血清同工型[-2]前列腺特异性抗原(p2PSA)及其衍生物%p2PSA和前列腺健康指数(PHI)在预测侵袭性前列腺癌(PCa)中的临床价值。
收集2015年8月至2018年5月北京大学第一医院322例PCa患者(包括143例经直肠超声引导下前列腺穿刺活检确诊为PCa的患者和179例行根治性前列腺切除术的患者)术前血清及基本临床资料。在自动免疫分析仪DxI800上检测所有患者的血清总前列腺特异性抗原(tPSA)、游离前列腺抗原(fPSA)及fPSA/tPSA(f/t)和p2PSA水平,然后计算%p2PSA和PHI。以前列腺病理结果作为评估PCa患者Gleason评分的金标准。采用受试者工作特征曲线(ROC)评估p2PSA、%p2PSA和PHI与传统标志物tPSA、fPSA和f/t相比预测侵袭性PCa(病理Gleason评分≥7)的能力。
在这些患者中,病理Gleason评分≥7的患者p2PSA、%p2PSA和PHI中位数水平显著高于Gleason评分<7的患者(p2PSA:30.22 ng/L对18.33 ng/L;%p2PSA:2.50对1.27;PHI:91.81对35.44;均P<0.01)。%p2PSA和PHI预测Gleason评分≥7的曲线下面积(AUC)(分别为0.770、0.760)高于传统指标tPSA、fPSA和f/t(AUC分别为0.648、0.536和0.693)。在经直肠超声引导下前列腺穿刺活检确诊为PCa的患者中,%p2PSA和PHI预测Gleason评分≥7的AUC(分别为0.808和0.801)高于传统指标tPSA、fPSA和f/t(AUC分别为0.729、0.655和0.665)。在接受根治性前列腺切除术的患者中,PHI和%p2PSA也有比传统指标更高的预测价值趋势。%p2PSA和PHI的AUC分别为0.798和0.744,而tPSA、fPSA和f/t的AUC分别为0.625、0.507和0.697。
与传统标志物tPSA、fPSA和f/t相比,%p2PSA和PHI对侵袭性PCa具有更高的预测价值,这可能有助于临床医生评估治疗方案并为患者制定更合适的管理计划。